Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced on the 23rd that the ‘establishment of a GMP clinical-grade gene therapy mass production system’ has been selected as a national task, pursuing joint R&D with Samsung Seoul Hospital (President Park Seung-woo).

In May, Reyon Pharmaceutical signed a ‘joint R&D cooperation agreement for mass production of GMP cell/gene therapy products’ with Samsung Seoul Hospital to continue active cooperation for joint R&D and cell/gene therapy production.

According to data from the Korea Health Industry Development Institute published in March this year, the global cell and gene therapy market is expected to grow at an average annual rate of about 49.1%, from $ 7.47 billion in 2021 to $ 55.59 billion in 2026.

Through this national project, the two companies plan to conduct joint research for cell and gene therapy technologies against rare and incurable diseases and collaborate to mass produce GMP clinical-grade cell/gene therapy.

Yoo Yonghwan, Representative Director of Reyon Pharmaceutical, said, "We are delighted to have been selected as a national project for research and development jointly conducted with top-notch medical staff and Samsung Medical Center's cell and gene therapy research institute, which has extensive research experience." He added, "Our company, which has mass production process technologies and facilities for high-purity pDNA stock solution, plans to develop innovative cell and gene therapies by laying the groundwork through mutual research cooperation with Samsung Medical Center."